SCHEMBL23924461

SCHEMBL23924461

N#CSCC(=O)c1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLOD2 O00469 2/20 0.54
PLOD3 O60568 1/20 0.49
PLOD1 Q02809 1/20 0.49
ALDH1A1 P00352 7/20 0.49
GAA P10253 2/20 0.49
APP P05067 1/20 0.49
HCAR3 P49019 1/20 0.49
HCAR2 Q8TDS4 1/20 0.49
F7 P08709 1/20 0.47
F3 P13726 1/20 0.47
SARM1 Q6SZW1 1/20 0.47
SIRT2 Q8IXJ6 1/20 0.47
SIRT6 Q8N6T7 1/20 0.47
SIRT1 Q96EB6 1/20 0.47
SIRT3 Q9NTG7 1/20 0.47
SIRT5 Q9NXA8 1/20 0.47
SIRT4 Q9Y6E7 1/20 0.47
MAPT P10636 6/20 0.46
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL955563 0.79 ALDH1A1 (0.56) ALDH1A1MAPTKMT2AMEN1USP2
SCHEMBL15564589 0.78 PLOD2 (0.59) PLOD2PLOD3PLOD1ALDH1A1GAA
SCHEMBL137583 0.78 PLOD2 (0.59) PLOD2PLOD3PLOD1ALDH1A1GAA
SCHEMBL3932662 0.75 PLOD2 (0.56) PLOD2PLOD3PLOD1ALDH1A1GAA
SCHEMBL29554726 0.75 PLOD2 (0.89) PLOD2PLOD3PLOD1ALDH1A1GAA
SCHEMBL7075878 0.75 PLOD2 (0.69) PLOD2PLOD3PLOD1ALDH1A1GAA
SCHEMBL10320930 0.75 PLOD2 (0.89) PLOD2PLOD3PLOD1ALDH1A1GAA
SCHEMBL5635739 0.74 PLOD2 (0.54) PLOD2PLOD3PLOD1ALDH1A1GAA
SCHEMBL6440012 0.73 PLOD2 (0.67) PLOD2PLOD3PLOD1ALDH1A1GAA
SCHEMBL9502043 0.73 PLOD2 (0.61) PLOD2PLOD3PLOD1ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118878514-A Heterocyclic compounds for modulating NR2F6 TES制药有限责任公司 2024-11-01 CN disclosed
EP-4110758-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 Tes Pharma S.r.l. (IT) 2023-01-04 EP disclosed
CN-115427394-A Heterocyclic compounds for modulating NR2F6 TES制药有限责任公司 2022-12-02 CN disclosed
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 PLOD2 4675/4885PLOD3 4265/4885PLOD1 4762/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 PLOD2 4675/4885PLOD3 4265/4885PLOD1 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.